On Friday, FDA Granted Accelerated Approval To Sanofi's Tzield (Teplizumab-mzwv) To Delay Decline In Endogenous (Own) Insulin Production In Children Aged 8 To 17 Years Recently Diagnosed With Stage 3 Type 1 Diabetes

Benzinga Newsdesk www.benzinga.com Positive 91.1%

Neg 0% Neu 0% Pos 91.1%

Accelerated approval in children aged eight to 17 years old recently diagnosed with stage 3 T1D to delay the decline in endogenous insulin production
Approval based on the PROTECT phase 3 study and additional data from the global clinical development program from over 900 patients who received Tzield

Comments

No comments yet. Be the first!